Immunoblotting results of tumor tissues from different treatment groups confirmed that IR‐LND@Lip effectively downregulated the expression of PD‐L1/TGF‐β dual immune proteins, concurrently leading to a reduction in the expression of the fibrotic marker COL1A1 (Figure 6B; Figure S24, Supporting Information). The gene discussed is PROS1; the disease is neoplasm.